新辅助性免疫化疗与新辅助性化疗在局部发达的食道状细胞癌中
Yuxin Yang1, Chang Yuan1, Bin Li1
1Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.
概括
与标准化疗放射治疗 (CROSS) 方案相比,新辅助性免疫化疗后的食道切除术 (NICE) 方案显示食道状细胞癌的生存结果有所改善. 辅助免疫疗法可以增强长期益处,特别是对于残留疾病患者.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 医学瘤学 医学瘤学
背景情况:
- 对食道癌的化学放射治疗,然后进行手术 (CROSS) 方案一直是食道状细胞癌的标准新辅助治疗.
- 新辅助性免疫化疗,其次是食管切除术 (NICE) 方案是具有有前途潜力的新兴替代方案.
研究的目的:
- 为了比较食道状细胞癌的NICE疗法与CROSS疗法的治疗反应和长期结果.
- 评估辅助治疗对NICE治疗后长期预后的影响.
主要方法:
- 在2018年1月至2022年4月期间接受NICE或CROSS治疗的患者的回顾性分析.
- 尼斯:卡姆雷利祖马布与卡博普拉丁和帕克利塔塞尔 (2个周期).
- 克罗斯:加博普拉丁和帕克利塔塞尔与同时进行放射治疗 (41.4 Gy). 每组有177名匹配患者.
主要成果:
- 病理性完全缓解 (pCR) 率相似 (20.9%的NICE与25.4%的CROSS).
- 尼斯 (NICE) 显示出优异的3年整体存活率 (73.5%与58.4%) 和癌症特异性存活率 (77.3%与64.3%).
- 复发率相似;然而,在NICE组中没有pCR的患者的生存率有所改善. 由免疫疗法驱动的NICE中较高的辅助疗法使用与更好的预后相关.
结论:
- 与CROSS疗法相比,NICE疗法可改善食道状细胞癌的存活率,并且具有类似的复发模式.
- 辅助免疫疗法可能对于在NICE后患有残留病理性疾病的患者获得长期益处至关重要.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
1.5K
相关概念视频
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
605
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
605
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K